Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Consumers, Employers, and Prescription Drugs During COVID-19: A Q&A With Arxcel's Chris Robbins
May 12th 2020How will coronavirus disease 2019 (COVID-19) affect prescription drug trends? The American Journal of Managed Care® (AJMC®) put questions to Chris Robbins, chief executive officer of Arxcel Consulting LLC, to review these subjects and more in a wrapup discussion after the Academy of Managed Care Pharmacy virtual meeting.
PBMs and Community Oncology: "We Just Can't Let Them Get Away With What They're Doing"
April 25th 2020Despite the immediate distraction from coronavirus disease 2019 (COVID-19), panelists at the 2020 Virtual Community Oncology Conference said community oncologists must keep pressure on pharmacy benefit managers (PBMs) as the 2020 campaign heats up—lest they lose the momentum to rein PBM practices within the umbrella of drug pricing reform.
COA Consensus: Telemedicine Is Here to Stay, but Practice Transformation Could Stall
April 25th 2020The bright spot of telemedicine's success during the coronavirus disease 2019 pandemic cannot overshadow the stresses on patients and practices, which will both have ongoing challenges when the pandemic ends, said panelists during a legislative update on day 2 of the 2020 Virtual Community Oncology Conference, convened by the Community Oncology Alliance.
COVID-19 Adds New Wrinkle in Shift to 2-Sided Risk in Oncology Care
April 23rd 2020Oncology practices could use more time to become accustomed to 2-sided risk even without a global pandemic, but the current crisis makes the need more urgent, say payment reform leaders at the Community Oncology Alliance virtual conference.
COVID-19 Upends Drug Purchasing Patterns, and More Disruption Likely, IQVIA Expert Says
April 20th 2020Douglas M. Long, MBA, vice president of industry relations for IQVIA, surveyed the effects of COVID-19 as he kicked off AMCP eLearning Days, a webinar series held in place of the annual meeting of the Academy of Managed Care Pharmacy (AMCP).
In Florida, Serving the Senior Population in Oncology Means Working Together
April 11th 2020“Quest for Value: Advancing Oncology Value-based Care,” this year’s first installment in the Institute for Value-Based Medicine (IVBM) from The American Journal of Managed Care®, zeroed in seniors, a population that’s growing not just in Florida but across the United States. Older Americans are more likely to develop cancer, but thanks to better detection and treatment, they are more likely to survive cancer, too.
Lack of Clarity on Medicare Advantage Palliative, Other Cancer Care Benefits Limits Consumer Uptake
April 11th 2020Benefits newly available under Medicare Advantage are not well-known to consumers and uptake has been limited. At the same time, CMS has propsed funding the hospice benefit differently, which would allow MA plans to “carve in” to this benefit, creating additional uncertainty.
Fauci Predicts Decline of COVID-19 Cases but Warns Against Complacency
April 8th 2020Anthony Fauci, MD, the director of the National Institute of Allergies and Infectious Diseases, said he thinks the country is on track to see a decline of coronavirus disease 2019 (COVID-19) but said life will not go back to the way it was before. Fauci was interviewed by the JAMA editor-in-chief, who also spoke with former Utah Governor Michael Leavitt about state and federal roles in a pandemic.
Medicare Advantage Gets 2021 Pay Bump Amid COVID-19 Rule Changes
April 7th 2020The rate increase comes as the agency is easing up on quality reporting requirements to give health sytems breathing room amid the pandemic. Monday’s announcement also clarified some payment changes for end-stage renal disease.
V-BID X for Employers: A Framework Designed to Promote Employee Access to High-Value Drugs, Services
April 2nd 2020Employers are showing great interest in value-based insurance design, as they recognize their role in shaping how their employees’ share of healthcare costs can affect what care they seek.
REDUCE-IT: Serum EPA Levels Hold Key to Vascepa's Dramatic CV Benefits
March 30th 2020Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood appear to explain why icosapent ethyl drives down the risk of a cardiovascular (CV) event, according to findings presented at the 2020 American College of Cardiology/World Congress of Cardiology Virtual Experience.
Evinacumab Brings Cholesterol to Near-Normal Levels for Patients With Rare, Inherited Condition
March 30th 2020Patients with homozygous familial hypercholesterolemia saw average reductions in low-density lipoprotein cholesterol of 47.1% over 24 weeks. Reductions began to appear as early as 2 weeks after patients started taking the drug in the double-blind trial.
Is Anatomy Destiny? Digging Deeper Into the ISCHEMIA Findings
March 30th 2020Results for ISCHEMIA and ISCHEMIA-CKD, first presented at the American Heart Association (AHA) and due to publish shortly, continued to generate discussion Sunday, when the 2020 American College of Cardiology / World Congress of Cardiology Virtual Experience featured a pair of online presentations with additional insights into these trials.
VICTORIA: With Vericiguat, Less CV Death, Heart Failure Hospitalization Among High-Risk Patients
March 28th 2020The trial showed that patients taking this novel therapy, an oral soluble guanylate cyclase stimulator, were 10% less likely to experience the primary outcome—a composite of death from cardiovascular (CV) causes or first hospitalization for HF—than those taking placebo. The drug could address the sickest patients through a mechanism that would take on HF progression.
VOYAGER-PAD: Less Risk of Events With Rivaroxaban After Treatment for Blocked Arteries
March 28th 2020The study, Vascular Outcomes Study of ASA Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD (VOYAGER-PAD), was designed to fill a knowledge gap: it asked whether a well-known therapy developed to prevent blood clots could be used to prevent events, including acute ischemia in the leg for patients after revascularization.
Hypertension-Related Deaths Rise in US, Especially in Rural South, Data Show
March 21st 2020Research highlighting these trends, based on 10 million death records pulled from a CDC database, will be presented at the American College of Cardiology’s Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC), which is taking place as a virtual meeting March 28-30.